Brain injuries commonly result in immense socioeconomic consequences due to the acute as well as persisting neurological deficits. To date, there are currently few pharmacological therapies of proven clinical benefit targeting the underlying pathophysiology occurring in the aftermath of subarachnoid hemorrhage (SAH), stroke, and traumatic brain injury (TBI). Although these brain injuries are exceedingly heterogeneous, some common pathophysiological phases may be identified. At disease onset, the primary ictus may cause initial neuronal, glial, and vascular injury, which is then followed by complex pathophysiological responses. The initial tissue injury is then exacerbated by secondary insults ...
Language: en
", language="en", issn="1664-2295", doi="10.3389/fneur.2018.00193", url="http://dx.doi.org/10.3389/fneur.2018.00193" }